---
trial_id: 731
discovery_date: 2022-04-24 16:23:21.896701
date: 2022-04-24 16:23:21.896701
title: "A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)"
summary: |
  <p>EudraCT Number: 2021-000028-36<br />Sponsor Protocol Number: P3-IMU-838-RMS-01<br />Sponsor Name: Immunic AG<br />Start Date: 2022-01-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000028-36/BG">BG</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000028-36'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2021-000028-36<br />Sponsor Protocol Number: P3-IMU-838-RMS-01<br />Sponsor Name: Immunic AG<br />Start Date: 2022-01-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000028-36/BG">BG</a> (Ongoing)</p>